| Primary |
| Product Used For Unknown Indication |
31.0% |
| Malaria Prophylaxis |
8.6% |
| Antifungal Prophylaxis |
7.8% |
| Pneumocystis Jiroveci Pneumonia |
6.9% |
| Prophylaxis |
6.0% |
| Hiv Infection |
5.2% |
| Pulmonary Tuberculosis |
5.2% |
| Cerebral Toxoplasmosis |
4.3% |
| Infection |
3.4% |
| Tuberculosis |
3.4% |
| Anaemia |
2.6% |
| Babesiosis |
2.6% |
| Renal Failure |
2.6% |
| Venous Thrombosis |
2.6% |
| Immunosuppression |
1.7% |
| Meningitis Bacterial |
1.7% |
| Nausea |
1.7% |
| Castleman's Disease |
0.9% |
| Cough |
0.9% |
| Epilepsy |
0.9% |
|
| Neutropenia |
12.9% |
| Blood Bilirubin Increased |
9.7% |
| Pancytopenia |
9.7% |
| Condition Aggravated |
6.5% |
| Liver Function Test Abnormal |
6.5% |
| Nausea |
6.5% |
| Pyrexia |
6.5% |
| Agranulocytosis |
3.2% |
| Alcohol Use |
3.2% |
| Angioedema |
3.2% |
| Depression |
3.2% |
| Diarrhoea |
3.2% |
| Drug Ineffective |
3.2% |
| Dysuria |
3.2% |
| Fatigue |
3.2% |
| Haematochezia |
3.2% |
| Hypercapnia |
3.2% |
| Leukopenia |
3.2% |
| Liver Disorder |
3.2% |
| Malaise |
3.2% |
|
| Secondary |
| Hiv Infection |
14.2% |
| Product Used For Unknown Indication |
11.5% |
| Antifungal Prophylaxis |
10.1% |
| Babesiosis |
9.2% |
| Cerebral Toxoplasmosis |
6.4% |
| Prophylaxis |
6.4% |
| Pneumonia |
4.6% |
| Renal Failure |
4.6% |
| Disseminated Cryptococcosis |
4.1% |
| Pneumocystis Jirovecii Pneumonia |
4.1% |
| Antiretroviral Therapy |
3.2% |
| Pneumocystis Jiroveci Infection |
3.2% |
| Thrombosis |
3.2% |
| Lymphoma |
2.8% |
| Toxoplasmosis |
2.8% |
| Bronchopulmonary Aspergillosis |
2.3% |
| Brain Oedema |
1.8% |
| Cytomegalovirus Infection |
1.8% |
| Drug Use For Unknown Indication |
1.8% |
| Nausea |
1.8% |
|
| Pathogen Resistance |
16.7% |
| Neutropenia |
9.5% |
| Renal Failure Acute |
9.5% |
| Acute Hepatic Failure |
7.1% |
| Renal Impairment |
7.1% |
| General Physical Health Deterioration |
4.8% |
| Hepatitis Cholestatic |
4.8% |
| Nephritic Syndrome |
4.8% |
| Rash Pustular |
4.8% |
| Syncope |
4.8% |
| Vaginal Haemorrhage |
4.8% |
| Asthenia |
2.4% |
| Blood Pressure Increased |
2.4% |
| Drug Hypersensitivity |
2.4% |
| Drug Ineffective |
2.4% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
2.4% |
| Ear Infection |
2.4% |
| Exposure During Pregnancy |
2.4% |
| Hepatic Cirrhosis |
2.4% |
| Immune Reconstitution Inflammatory Syndrome |
2.4% |
|
| Concomitant |
| Hiv Infection |
27.5% |
| Product Used For Unknown Indication |
23.4% |
| Drug Use For Unknown Indication |
21.4% |
| Prophylaxis |
4.4% |
| Antifungal Prophylaxis |
4.1% |
| Mycobacterium Avium Complex Infection |
3.4% |
| Acute Myeloid Leukaemia |
2.0% |
| Bone Marrow Conditioning Regimen |
1.7% |
| Cytomegalovirus Infection |
1.4% |
| Multiple Myeloma |
1.3% |
| Tuberculosis |
1.2% |
| Chronic Lymphocytic Leukaemia |
1.1% |
| Nausea |
1.0% |
| Hypertension |
1.0% |
| Pain |
1.0% |
| Infection Prophylaxis |
0.9% |
| Diarrhoea |
0.9% |
| Antibiotic Prophylaxis |
0.9% |
| Cerebral Toxoplasmosis |
0.8% |
| Hypersensitivity |
0.8% |
|
| Vomiting |
17.7% |
| Thrombocytopenia |
8.6% |
| Pyrexia |
6.1% |
| Renal Failure |
6.1% |
| Renal Failure Acute |
6.1% |
| Respiratory Failure |
6.1% |
| Neutropenia |
5.6% |
| Hypokalaemia |
5.1% |
| Immune Reconstitution Syndrome |
5.1% |
| Venoocclusive Disease |
5.1% |
| Meningitis Cryptococcal |
3.5% |
| Renal Impairment |
3.5% |
| Epistaxis |
3.0% |
| Platelet Count Decreased |
3.0% |
| Sepsis |
3.0% |
| Drug Ineffective |
2.5% |
| Febrile Neutropenia |
2.5% |
| Renal Tubular Necrosis |
2.5% |
| Viral Haemorrhagic Cystitis |
2.5% |
| White Blood Cell Count Decreased |
2.5% |
|
| Interacting |
| Bk Virus Infection |
100.0% |
|
|
